Blue Jet Healthcare Ltd
Blue Jet Healthcare Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Get Blue Jet Healthcare Ltd's next results in your feed
Guidance rank: #23 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Blue Jet Healthcare Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue from Operations: ₹3,757 million, a 127.1% year-on-year (YoY) increase from ₹1,655 million in Q2 FY26 (Page 13). Q2 FY27 Financials:.
From Blue Jet Healthcare Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.
How did Blue Jet Healthcare's revenue grow in the September 2026 quarter?
- Q2 FY27 Revenue from Operations: ₹3,757 million, a 127.1% year-on-year (YoY) increase from ₹1,655 million in Q2 FY26 (Page 13).
- Highest Quarterly Sales reported in Q2 FY27 (Page 7).
- Revenue growth driven by Pharma Intermediates & API category (+322% YoY) and Contrast Media (+80% YoY) in Q2 FY27 (Page 8).
- H1 FY27 Revenue from Operations: ₹6,689 million, up 28.6% YoY from ₹5,202 million in H1 FY26 (Page 13).
2 more points from Blue Jet Healthcare Ltd's call on revenue
Create a free account to keep reading this call
What happened to Blue Jet Healthcare's margins in Q2 FY27?
See what Blue Jet Healthcare Ltd said on profitability & margins — free account, 30 seconds.
What capex is Blue Jet Healthcare planning?
- Acquisition of land near Vizag and groundbreaking of the project in 2026 (Page 17).
- Company successfully commissioned Plant 6 at Ambernath in 2021 (Page 17).
- R&D centre at Hyderabad is operational with 40 resources onboarded and activities started (Page 6).
- Plans to build additional production capacity to meet increasing customer demand (Page 40).
- Raised ₹8,000 mn via QIP in 2026 for expansion (Page 17).
2 more points from Blue Jet Healthcare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Blue Jet Healthcare raising money or cutting debt?
See what Blue Jet Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Blue Jet Healthcare's order book?
See what Blue Jet Healthcare Ltd said on order book & pipeline — free account, 30 seconds.
Blue Jet Healthcare Ltd — Quarterly revenue & net profit
Blue Jet Healthcare Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 376 |
| Operating profit (EBITDA) | 119 |
| Operating margin | 31.6% |
| Profit before tax | 137 |
| Net profit (PAT) | 103 |
| EPS (₹) | 5.46 |
Source: Blue Jet Healthcare Ltd's results filing to NSE (standalone), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹376 Cr, net profit ₹103 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Blue Jet Health's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Symbiotec Pharma (Q2 FY27)
280 Cr, up 43% YoY from Rs. Key investor presentation takeaways from Symbiotec Pharmalab Ltd's Q2 FY27 investor presentation — and how it ranks against sector p
- Hester Bios (Q2 FY27)
Standalone Q2 FY27 revenue: INR 829.28 million, up 28% YoY (from INR 645.79 million in Q2 FY26). Key results statement takeaways from Hester Biosciences Ltd's Q
- Glenmark Pharmaceuticals (Q2 FY27)
42,473 million, down 29.8% YoY. Key investor presentation takeaways from Glenmark Pharmaceuticals Ltd's Q2 FY27 investor presentation — and how it ranks against
- Windlas Biotech (Q2 FY27)
264 Cr, a 19% YoY increase from Rs. Key investor presentation takeaways from Windlas Biotech Ltd's Q2 FY27 investor presentation — and how it ranks against sect
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Blue Jet Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Blue Jet Healthcare Ltd Q2 FY27 results?
Q2 FY27 Revenue from Operations: ₹3,757 million, a 127.1% year-on-year (YoY) increase from ₹1,655 million in Q2 FY26 (Page 13). Q2 FY27 Financials:.
What is Blue Jet Healthcare Ltd share price analysis?
Blue Jet Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 42.9 with a market cap of ₹10,067 Cr. Investors should review the full earnings analysis for detailed insights.
Is Blue Jet Healthcare Ltd planning capital expenditure?
Acquisition of land near Vizag and groundbreaking of the project in 2026 (Page 17).
Keep Blue Jet Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.